

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Nivolumab with ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

Final Stakeholder list

Consultees	Commontators (no right to submit or
Consultees	Commentators (no right to submit or appeal)
Company	General
Bristol Myers and Squibb (nivolumab and ipilimumab)	 All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation
 Patient/carer groups Black Health Agency for Equality Bladder and Bowel Community Bladder and Bowel UK Bowel Cancer UK Cancer Black Care Cancer Equality Cancer52 Childhood Cancer Parents Alliance Children with Cancer Colostomy UK Contact Helen Rollason Cancer Charity IA: lleostomy and Internal Pouch Association Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres 	 Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Promega Scottish Medicines Consortium Scottish Society of Gastroenterology Welsh Government Welsh Health Specialised Services Committee
 Marie Curie Pelican Cancer Foundation Red Trouser Day South Asian Health Foundation Specialised Healthcare Alliance Teenage Cancer Trust Young Lives vs Cancer Tenovus Cancer Care Healthcare Professional groups Association of Cancer Physicians Association of Coloproctology of Great Britain and Ireland British Geriatrics Society 	 Possible comparator companies Amgen (panitumumab) Dr Reddy's Laboratories (capecitabine) Glenmark Pharmaceuticals (capecitabine) Medac (folinic acid, fluorouracil, irinotecan, oxaliplatin) Merck (cetuximab) MSD (pembrolizumab) Pfizer (irinotecan) Ranbaxy (irinotecan, oxaliplatin) Seacross Pharmaceuticals (irinotecan, oxaliplatin)

Final stakeholder list for the evaluation of nivolumab with ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] Issue date: April 2024 © National Institute for Health and Care Excellence 2024. All rights reserved.



Consultees Commentators (no right to submit or appeal) British Institute for Radiology Relevant research groups **British Oncology Pharmacy** Bowel Research UK Association Cochrane Colorectal Group British Psychosocial Oncology Society British Society of Gastroenterology Genomics England British Society of Paediatric Institute of Cancer Research Gastroenterology, Hepatology and MRC Clinical Trials Unit Nutrition National Institute for Health Research Cancer Research UK Children's Cancer & Leukaemia Group Associated Public Health Groups **Public Health Wales** Neonatal and Paediatric Pharmacists Group **UK Health Security Agency** Primary Care Society for Gastroenterology Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers **UK Clinical Pharmacy Association** UK Oncology Nursing Society Department of Health and Social Care NHS England


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Final stakeholder list for the evaluation of nivolumab with ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] Issue date: April 2024 © National Institute for Health and Care Excellence 2024. All rights reserved.



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG)..

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederationand the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.